Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie Fox

Showing results (151-160 of 182) with videos related to

Pageof 19
Sort By:
HIV Medicine|December 12, 2022
BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022Laura Waters, Alan Winston, Iain Reeves, et al.
Nature Immunology|July 27, 2021
Epigenetic scars of CD8<sup>+</sup> T cell exhaustion persist after cure of chronic infection in humansKathleen B Yates, Pierre Tonnerre, Genevieve E Martin, et al.
Blood|December 21, 2012
Early and nonreversible decrease of CD161++ /MAIT cells in HIV infectionCormac Cosgrove, James E Ussher, Andri Rauch, et al.
Kidney International Reports|May 2, 2022
Genetic Variants of <i>APOL1</i> Are Major Determinants of Kidney Failure in People of African Ancestry With HIVRachel K Y Hung, Elizabeth Binns-Roemer, John W Booth, et al.
Kidney International Reports|December 19, 2024
Corrigendum to "Genetic Variants of <i>APOL1</i> Are Major Determinants of Kidney Failure in People of African Ancestry With HIV" [<i>Kidney International Reports</i> Volume 7, Issue 4, April 2022, Pages 786-796]Rachel K Y Hung, Elizabeth Binns-Roemer, John W Booth, et al.
HIV Medicine|January 7, 2026
Effectiveness and safety of two-drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE-2 studyCristina Mussini, Cassidy Henegar, Lambert Assoumou, et al.
Kidney International Reports|March 8, 2022
Sickle Cell Trait and Kidney Disease in People of African Ancestry With HIVRachel K Y Hung, Elizabeth Binns-Roemer, John W Booth, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2022
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized TrialLaura Waters, Lambert Assoumou, Ana González-Cordón, et al.
Kidney International Reports|August 15, 2022
GSTM1 Copy Number and Kidney Disease in People With HIVRachel K Y Hung, Kerry-Lee Rosenberg, Victor David, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 19, 2023
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 TrialAbiu Sempere, Lambert Assoumou, Ana González-Cordón, et al.
Pageof 19

Showing results (151-160 of 182) with videos related to

Sort By:
Pageof 19
HIV Medicine|December 12, 2022
BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022Laura Waters, Alan Winston, Iain Reeves, et al.
Nature Immunology|July 27, 2021
Epigenetic scars of CD8<sup>+</sup> T cell exhaustion persist after cure of chronic infection in humansKathleen B Yates, Pierre Tonnerre, Genevieve E Martin, et al.
Blood|December 21, 2012
Early and nonreversible decrease of CD161++ /MAIT cells in HIV infectionCormac Cosgrove, James E Ussher, Andri Rauch, et al.
Kidney International Reports|May 2, 2022
Genetic Variants of <i>APOL1</i> Are Major Determinants of Kidney Failure in People of African Ancestry With HIVRachel K Y Hung, Elizabeth Binns-Roemer, John W Booth, et al.
Kidney International Reports|December 19, 2024
Corrigendum to "Genetic Variants of <i>APOL1</i> Are Major Determinants of Kidney Failure in People of African Ancestry With HIV" [<i>Kidney International Reports</i> Volume 7, Issue 4, April 2022, Pages 786-796]Rachel K Y Hung, Elizabeth Binns-Roemer, John W Booth, et al.
HIV Medicine|January 7, 2026
Effectiveness and safety of two-drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE-2 studyCristina Mussini, Cassidy Henegar, Lambert Assoumou, et al.
Kidney International Reports|March 8, 2022
Sickle Cell Trait and Kidney Disease in People of African Ancestry With HIVRachel K Y Hung, Elizabeth Binns-Roemer, John W Booth, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2022
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized TrialLaura Waters, Lambert Assoumou, Ana González-Cordón, et al.
Kidney International Reports|August 15, 2022
GSTM1 Copy Number and Kidney Disease in People With HIVRachel K Y Hung, Kerry-Lee Rosenberg, Victor David, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 19, 2023
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 TrialAbiu Sempere, Lambert Assoumou, Ana González-Cordón, et al.
Pageof 19